Spexib (Ceritinib)

Medicine Overview

Spexib, formulated with Ceritinib, is a targeted therapy designed for patients with ALK-positive non-small cell lung cancer. It blocks cancer cell growth, slowing tumor progression and improving patient outcomes. Suitable for adults who require effective oral treatment, it enhances quality of life with a convenient daily regimen. Key benefits include strong ALK inhibition, oral dosing convenience, and improved disease management. Spexib is an essential solution for precision lung cancer therapy.